CAMBRIDGE, MA — March 29, 2005 – Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan Crane, Chairman and Chief Executive Officer, will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference on Monday April 4, 2005 at 3:15 pm Eastern Standard Time at the Millennium Broadway Hotel, New York, NY. A live webcast of the presentation will be available on the “Investors” section of the Company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately thirty minutes after the event and will be available through May 4, 2005.

About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products. The Company’s most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of novel discovery and development candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit our website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Momenta Pharmaceuticals, Inc.

Contact:
Michael Lawless
Momenta Pharmaceuticals, Inc.
617-395-5189

Press Contact
press@momentapharma.com

Company Fact Sheet

Technology Fact Sheet

Regulatory Fact Sheet